This trial is testing a new combination of treatments for men with castration sensitive prostate cancer that has spread to a limited number of sites. The goal is to see if this new combination is safe and effective.
1 Primary · 5 Secondary · Reporting Duration: 24 months after enrollment
29 Total Participants · 1 Treatment Group
Primary Treatment: Olaparib · No Placebo Group · Phase 2
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: